PD-1 and its ligands in ILC2-mediated airway inflammation in asthma: context-dependent mechanisms and therapeutic implications
Frontiers in Pharmacology · 04.11.2026 · 17
DOI: 10.3389/fphar.2026.1988503 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.11.2026. Verfasst von Liu Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Wuhou District People's Hospital, Chengdu, China. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Group 2 innate lymphoid cells (ILC2s) contribute to type 2 asthma through rapid production of interleukin-5 and interleukin-13, but the inhibitory pathways that restrain pathogenic ILC2 activity remain incompletely defined. Most evidence for programmed cell death protein 1 (PD-1)-mediated inhibition of ILC2s comes from murine models, humanized mice, and stimulated or expanded human cells; cell-resolved expression and functional engagement of PD-1 have not been established in freshly isolated airway ILC2s from well-characterized asthma cohorts. In available experimental systems, PD-1 engagement suppresses ILC2 proliferation and cytokine production, whereas programmed death-ligand 1 (PD-L1) displayed by ILC2s can act outwardly on PD-1-positive CD4-positive T cells. Programmed death-ligand 2 (PD-L2) can inhibit isolated ILC2s through PD-1, but its whole-lung effects also involve dendritic-cell IL-12 regulation and RGMb-dependent respiratory tolerance. Interpretation therefore depends on the ligand-bearing and responding cells, ligand form, tissue compartment, disease stage, and asthma endotype. This review examines cell-intrinsic PD-1 signaling, ligand-specific cellular interactions, immunometabolic regulation, and translational constraints. The current evidence supports preclinical investigation rather than clinical readiness; direct validation in human airway ILC2s, definition of receptor-proximal signaling, and a predictive biomarker are prerequisites for therapeutic development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wuhou District People's Hospital, Chengdu, China.
- Wuhou District Health Hospital for Woman & Children, Chengdu, China.
Zitieren
APA
Ma, L., Zhang, M., Gou, S., & He, Q. (2026). PD-1 and its ligands in ILC2-mediated airway inflammation in asthma: context-dependent mechanisms and therapeutic implications. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1988503
Vancouver
Ma L, Zhang M, Gou S, He Q. PD-1 and its ligands in ILC2-mediated airway inflammation in asthma: context-dependent mechanisms and therapeutic implications. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1988503
BibTeX
@article{Ma2026,
author = {Ma, Liu and Zhang, Mingrong and Gou, Shengdong and He, Qifu},
title = {PD-1 and its ligands in ILC2-mediated airway inflammation in asthma: context-dependent mechanisms and therapeutic implications},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1988503}
}
EUVIMED